As DDRi and ADC combination therapies gain momentum, our team of experts have conducted the following analysis, using Beacon DDR data, to explore this promising approach. With its potential to deliver more targeted and tolerable treatments, understanding the synergy between DDR targets and ADC payloads is crucial to maximizing therapeutic success.
The infographic includes:
-
- An overview of the growth of ADC-DDRi clinical trials since the first trial initiation in 2015
- Analysis of DDR targets and payloads to help identify best combinations to maximize therapeutic benefit
- Insight into top biomarkers associated with combination trials
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
You may also be interested in...
The 2024 DDR H1 Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
